Abstract
Previous research suggests separate neural networks for implicit (non-declarative) and explicit (declarative) memory processes. A core cognitive impairment in mild to moderate Alzheimers disease (AD) is a pronounced declarative memory and learning deficit with relative preservation of non-declarative memory. Cholinesterase inhibitors has been purported to enhance cognitive function, and previous clinical trials consistently showed that donepezil, a reversible inhibitor of acetylcholinesterase (AChE), led to statistically significant improvements in cognition and patient function. This prospective pilot study is a randomized, double blind, placebo-controlled clinical trial investigating 10 patients with AD. Our purpose was to examine the relationship between declarative and non-declarative capability with particular emphasis on implicit sequence learning. Patients were assessed at baseline and again at 4-weeks. After participants baseline data were obtained, each was double-blindly randomized to one of two groups: donepezil or placebo. At baseline participants were tested with two outcome measures (Serial Reaction Time Task, Alzheimers Disease Assessment Scale-Cognitive Subscale). Participants were given either 5 mg donepezil or an identically appearing placebo to be taken nightly for 4 weeks (28 tablets), and then retested. The donepezil group demonstrated a greater likelihood of increases in both nondeclarative and declarative processes. The placebo group was mixed without clearly definable trends or patterns. When the data were examined for coincidental changes in the two outcome measures together they are suggestive of a benefit from donepezil treatment for non-declarative and declarative processes.
Keywords: Implicit learning, serial reaction time task, procedural memory, declarative memory, Alzheimer's disease, cognition
Current Alzheimer Research
Title: Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?
Volume: 4 Issue: 3
Author(s): Carolee J. Winstein, Kirk R. Bentzen, Lara Boyd and Lon S. Schneider
Affiliation:
Keywords: Implicit learning, serial reaction time task, procedural memory, declarative memory, Alzheimer's disease, cognition
Abstract: Previous research suggests separate neural networks for implicit (non-declarative) and explicit (declarative) memory processes. A core cognitive impairment in mild to moderate Alzheimers disease (AD) is a pronounced declarative memory and learning deficit with relative preservation of non-declarative memory. Cholinesterase inhibitors has been purported to enhance cognitive function, and previous clinical trials consistently showed that donepezil, a reversible inhibitor of acetylcholinesterase (AChE), led to statistically significant improvements in cognition and patient function. This prospective pilot study is a randomized, double blind, placebo-controlled clinical trial investigating 10 patients with AD. Our purpose was to examine the relationship between declarative and non-declarative capability with particular emphasis on implicit sequence learning. Patients were assessed at baseline and again at 4-weeks. After participants baseline data were obtained, each was double-blindly randomized to one of two groups: donepezil or placebo. At baseline participants were tested with two outcome measures (Serial Reaction Time Task, Alzheimers Disease Assessment Scale-Cognitive Subscale). Participants were given either 5 mg donepezil or an identically appearing placebo to be taken nightly for 4 weeks (28 tablets), and then retested. The donepezil group demonstrated a greater likelihood of increases in both nondeclarative and declarative processes. The placebo group was mixed without clearly definable trends or patterns. When the data were examined for coincidental changes in the two outcome measures together they are suggestive of a benefit from donepezil treatment for non-declarative and declarative processes.
Export Options
About this article
Cite this article as:
Carolee J. Winstein , Kirk R. Bentzen , Lara Boyd and Lon S. Schneider , Does the Cholinesterase Inhibitor, Donepezil, Benefit Both Declarative and Non-Declarative Processes in Mild to Moderate Alzheimers Disease?, Current Alzheimer Research 2007; 4 (3) . https://dx.doi.org/10.2174/156720507781077296
DOI https://dx.doi.org/10.2174/156720507781077296 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structural MRI Biomarkers of Mild Cognitive Impairment from Young Elders to Centenarians
Current Alzheimer Research Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Antiplatelets in Stroke Prevention
Current Vascular Pharmacology Acetylcholinesterase: A Primary Target for Drugs and Insecticides
Mini-Reviews in Medicinal Chemistry Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine Correlation of Alzheimer-like Tau Hyperphosphorylation and fMRI Bold Intensity
Current Alzheimer Research Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies
Current Alzheimer Research Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment
Current Pharmaceutical Design The Protective Role of Heme Oxygenase-1 in Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Filling the Gaps in the Aβ Cascade Hypothesis of Alzheimers Disease
Current Alzheimer Research The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Hybrid PET Imaging in Neurologic Disease: PET/MRI Rather than PET/CT
Current Medical Imaging Neurotrophins in the Lower Urinary Tract: Becoming of Age
Current Neuropharmacology Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology Nicotinic Acetylcholine Receptor Interaction with β -Amyloid: Molecular, Cellular, and Physiological Consequences
Current Alzheimer Research Influence of Oxidative Stress on Catalytic and Non-glycolytic Functions of Glyceraldehyde-3-phosphate Dehydrogenase
Current Medicinal Chemistry MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Biological Markers of Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research